COMPANY PROFILE

Cepheid

Explore full profile

A molecular diagnostics company providing molecular systems and tests for organisms and genetic-based diseases

Sunnyvale, United StatesFounded 1996Biotech & Life Sciences

Valuation $2.5–5B Last recorded · 2016

Revenue $500M–1B Latest reported FY

Headcount 2–5k Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Cepheid

Cepheid is a pioneering company in the healthcare diagnostics industry, specializing in molecular diagnostic testing. The company operates in the global healthcare market, providing innovative solutions that enable healthcare professionals to obtain fast, accurate, and easy-to-use test results. Cepheid's primary clients include hospitals, clinics, and laboratories, ranging from large core labs to smaller, near-patient settings. The company's mission is to ensure that everyone, regardless of location, has access to high-quality diagnostic tests.

Cepheid's business model revolves around its flexible testing platform, which supports a wide range of diagnostic tests. This platform is designed to streamline workflows and improve patient management by delivering rapid test results. The company generates revenue by selling its diagnostic systems and test cartridges to healthcare providers. Additionally, Cepheid offers educational resources and tools to help healthcare professionals maximize the benefits of its products.

The company's Global Access Program underscores its commitment to making high-quality diagnostic tests accessible to underserved populations worldwide. By focusing on faster and more efficient testing solutions, Cepheid aims to improve patient outcomes and support better decision-making in healthcare.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 1996
Headquarters: Sunnyvale, United States
Employees: 4,665
Open positions: 132
Dealroom signal: 68.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Infections and Infectious Diseases, Genetics and genomics, Biotech and Pharma, Hard Tech, DT and LS, uk is8 life sciences, science-based
Business model: Manufacturing
Client focus: b2b
Investment activity: 2 companies, latest Dec 2021
Capital deployed: —
Preferred round: ACQUISITION
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
GRANTOther financing	Jul 2021	$27M	—	US Biomedical Advanced Research and Development Authority	—
GRANTOther financing	Sep 2020	$1M	—	Undisclosed	—

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Cepheid website traffic

Latest recorded traffic for Cepheid is 100K monthly website visits, down 16.7% over the last three months. Cepheid's team declined 2.9% over the past year.

Latest monthly visits100K 3-month web change-16.7% 1-year team growth-2.9%

Monthly website visitsApr 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

EHS EngineerLodi, CA · Other · Sep 7, 2026 Territory ManagerLisboa, Lisbon, Portugal · Other · Sep 7, 2026 Senior IT Portfolio & Governance LeadCharlotte, NC · Finance · Sep 6, 2026 Senior AccountantNew York, NY · Accounting · Sep 5, 2026 Senior IT Portfolio & Governance LeadSalt Lake City, UT · Finance · Sep 5, 2026 Senior IT Portfolio & Governance LeadBoston, MA · Finance · Sep 4, 2026 Senior IT Portfolio & Governance LeadMilwaukee, WI · Finance · Sep 3, 2026 Senior IT Portfolio & Governance LeadMiami, FL · Finance · Sep 3, 2026

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
F2F2GDiscovers and develops novel drugs for the treatment of life-threatening fungal diseases	Manchester, United Kingdom	Operational	103	$355M	$500M
HTHarness TherapeuticsA private biotechnology company, headquartered in Cambridge-UK, focused on the development of a novel class of therapeutic RNAs	Babraham, United Kingdom	Operational
SESeniscaRNA senotherapeutics reversing cellular aging for disease treatment	Exeter, United Kingdom	Operational
ETEleven TherapeuticsResearch firm that unleashes the power of RNAi technology that helps to create precise and durable therapeutics	Cambridge, United Kingdom	Operational
BGBase GenomicsEpigenetic technology for early cancer detection from blood	Oxford, United Kingdom	Acquired
OBOchre BioDevelops RNA therapies for chronic liver diseases, a leading cause of death globally	Oxford, United Kingdom	Operational
MIMicrofluidXTackling the problems of process control, scalability, and cost associated with cell bioprocessing	Stevenage, United Kingdom	Operational
NTNucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine	Oxford, United Kingdom	Operational